Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial

Jessica Werth Cook, Bonnie Spring, Dennis E. McChargue, Belinda Borrelli, Brian Hitsman, Raymond Niaura, Nancy J. Keuthen, Jean Kristeller

Research output: Contribution to journalArticle

Abstract

Rationale: Fluoxetine improves affect in clinical syndromes such as depression and premenstrual dysphoric disorder. Little is known about fluoxetine's influence on mood changes after quitting smoking, which often resemble sub-clinical depression. Objectives: The present study, a re-analysis of previously published data (Niaura et al. 2002), examined fluoxetine's effect on changes in negative and positive affect following quitting smoking. Methods: Adult smokers (n=175) without clinically significant depression were randomized on a double-blind basis to receive fluoxetine hydrochloride (30 or 60 mg daily) or placebo for 10 weeks in combination with cognitive-behavioral therapy (CBT) for smoking cessation. We postulated that fluoxetine would beneficially influence post-cessation changes in positive and negative affect. Results: Mood change across treatment was analyzed using mixed linear modeling controlling for initial level of nicotine dependence, plasma fluoxetine metabolites, and change in cotinine (a nicotine metabolite) at each visit. Relative to placebo, those on 60 mg fluoxetine experienced an elevation in positive affect that increased across time [t(526)=2.50, P=0.01], and a reduction in negative affect that returned to baseline across time [t(524)=2.26, P=0.02]. There were no differences between 30 mg and placebo on changes in positive or negative affect. Conclusions: Results indicate that 60 mg of fluoxetine improves both positive and negative mood states after quitting smoking and that diminished positive affect may be an overlooked affective response to smoking cessation.

Original languageEnglish (US)
Pages (from-to)153-159
Number of pages7
JournalPsychopharmacology
Volume173
Issue number1-2
DOIs
StatePublished - Apr 2004

Fingerprint

Fluoxetine
Smoking Cessation
Smoking
Placebos
Depression
Cotinine
Tobacco Use Disorder
Cognitive Therapy
Nicotine

Keywords

  • Fluoxetine
  • Negative affect
  • Positive affect
  • Smoking cessation

ASJC Scopus subject areas

  • Pharmacology

Cite this

Cook, J. W., Spring, B., McChargue, D. E., Borrelli, B., Hitsman, B., Niaura, R., ... Kristeller, J. (2004). Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. Psychopharmacology, 173(1-2), 153-159. https://doi.org/10.1007/s00213-003-1711-8

Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. / Cook, Jessica Werth; Spring, Bonnie; McChargue, Dennis E.; Borrelli, Belinda; Hitsman, Brian; Niaura, Raymond; Keuthen, Nancy J.; Kristeller, Jean.

In: Psychopharmacology, Vol. 173, No. 1-2, 04.2004, p. 153-159.

Research output: Contribution to journalArticle

Cook, JW, Spring, B, McChargue, DE, Borrelli, B, Hitsman, B, Niaura, R, Keuthen, NJ & Kristeller, J 2004, 'Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial', Psychopharmacology, vol. 173, no. 1-2, pp. 153-159. https://doi.org/10.1007/s00213-003-1711-8
Cook, Jessica Werth ; Spring, Bonnie ; McChargue, Dennis E. ; Borrelli, Belinda ; Hitsman, Brian ; Niaura, Raymond ; Keuthen, Nancy J. ; Kristeller, Jean. / Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. In: Psychopharmacology. 2004 ; Vol. 173, No. 1-2. pp. 153-159.
@article{54262412d642476f932d559d2a3322e8,
title = "Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial",
abstract = "Rationale: Fluoxetine improves affect in clinical syndromes such as depression and premenstrual dysphoric disorder. Little is known about fluoxetine's influence on mood changes after quitting smoking, which often resemble sub-clinical depression. Objectives: The present study, a re-analysis of previously published data (Niaura et al. 2002), examined fluoxetine's effect on changes in negative and positive affect following quitting smoking. Methods: Adult smokers (n=175) without clinically significant depression were randomized on a double-blind basis to receive fluoxetine hydrochloride (30 or 60 mg daily) or placebo for 10 weeks in combination with cognitive-behavioral therapy (CBT) for smoking cessation. We postulated that fluoxetine would beneficially influence post-cessation changes in positive and negative affect. Results: Mood change across treatment was analyzed using mixed linear modeling controlling for initial level of nicotine dependence, plasma fluoxetine metabolites, and change in cotinine (a nicotine metabolite) at each visit. Relative to placebo, those on 60 mg fluoxetine experienced an elevation in positive affect that increased across time [t(526)=2.50, P=0.01], and a reduction in negative affect that returned to baseline across time [t(524)=2.26, P=0.02]. There were no differences between 30 mg and placebo on changes in positive or negative affect. Conclusions: Results indicate that 60 mg of fluoxetine improves both positive and negative mood states after quitting smoking and that diminished positive affect may be an overlooked affective response to smoking cessation.",
keywords = "Fluoxetine, Negative affect, Positive affect, Smoking cessation",
author = "Cook, {Jessica Werth} and Bonnie Spring and McChargue, {Dennis E.} and Belinda Borrelli and Brian Hitsman and Raymond Niaura and Keuthen, {Nancy J.} and Jean Kristeller",
year = "2004",
month = "4",
doi = "10.1007/s00213-003-1711-8",
language = "English (US)",
volume = "173",
pages = "153--159",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1-2",

}

TY - JOUR

T1 - Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial

AU - Cook, Jessica Werth

AU - Spring, Bonnie

AU - McChargue, Dennis E.

AU - Borrelli, Belinda

AU - Hitsman, Brian

AU - Niaura, Raymond

AU - Keuthen, Nancy J.

AU - Kristeller, Jean

PY - 2004/4

Y1 - 2004/4

N2 - Rationale: Fluoxetine improves affect in clinical syndromes such as depression and premenstrual dysphoric disorder. Little is known about fluoxetine's influence on mood changes after quitting smoking, which often resemble sub-clinical depression. Objectives: The present study, a re-analysis of previously published data (Niaura et al. 2002), examined fluoxetine's effect on changes in negative and positive affect following quitting smoking. Methods: Adult smokers (n=175) without clinically significant depression were randomized on a double-blind basis to receive fluoxetine hydrochloride (30 or 60 mg daily) or placebo for 10 weeks in combination with cognitive-behavioral therapy (CBT) for smoking cessation. We postulated that fluoxetine would beneficially influence post-cessation changes in positive and negative affect. Results: Mood change across treatment was analyzed using mixed linear modeling controlling for initial level of nicotine dependence, plasma fluoxetine metabolites, and change in cotinine (a nicotine metabolite) at each visit. Relative to placebo, those on 60 mg fluoxetine experienced an elevation in positive affect that increased across time [t(526)=2.50, P=0.01], and a reduction in negative affect that returned to baseline across time [t(524)=2.26, P=0.02]. There were no differences between 30 mg and placebo on changes in positive or negative affect. Conclusions: Results indicate that 60 mg of fluoxetine improves both positive and negative mood states after quitting smoking and that diminished positive affect may be an overlooked affective response to smoking cessation.

AB - Rationale: Fluoxetine improves affect in clinical syndromes such as depression and premenstrual dysphoric disorder. Little is known about fluoxetine's influence on mood changes after quitting smoking, which often resemble sub-clinical depression. Objectives: The present study, a re-analysis of previously published data (Niaura et al. 2002), examined fluoxetine's effect on changes in negative and positive affect following quitting smoking. Methods: Adult smokers (n=175) without clinically significant depression were randomized on a double-blind basis to receive fluoxetine hydrochloride (30 or 60 mg daily) or placebo for 10 weeks in combination with cognitive-behavioral therapy (CBT) for smoking cessation. We postulated that fluoxetine would beneficially influence post-cessation changes in positive and negative affect. Results: Mood change across treatment was analyzed using mixed linear modeling controlling for initial level of nicotine dependence, plasma fluoxetine metabolites, and change in cotinine (a nicotine metabolite) at each visit. Relative to placebo, those on 60 mg fluoxetine experienced an elevation in positive affect that increased across time [t(526)=2.50, P=0.01], and a reduction in negative affect that returned to baseline across time [t(524)=2.26, P=0.02]. There were no differences between 30 mg and placebo on changes in positive or negative affect. Conclusions: Results indicate that 60 mg of fluoxetine improves both positive and negative mood states after quitting smoking and that diminished positive affect may be an overlooked affective response to smoking cessation.

KW - Fluoxetine

KW - Negative affect

KW - Positive affect

KW - Smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=2342653442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342653442&partnerID=8YFLogxK

U2 - 10.1007/s00213-003-1711-8

DO - 10.1007/s00213-003-1711-8

M3 - Article

VL - 173

SP - 153

EP - 159

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1-2

ER -